This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"The tick-borne parasite Theileria annulata can cause life-threatening illness in cows. Buparvaquone is the only available drug treatment, but the incidence of buparvaquone (BPQ) resistance is increasing so alternative therapies are needed. To help, researchers recently tested the efficacy of the anti-malaria drug artemisinin and its derivatives against T. annulata infection. Artemisinin itself wasn’t effective, but all of its derivatives were able to selectively kill parasite-infected cells. Artesunate (ARS) and dihydroartemisinin (DHART) were especially potent and either drug could act synergistically with BPQ, enhancing the parasite-killing effects of the individual compounds. Investigation of the mechanism revealed that ARS and DHART caused oxidative stress and DNA damage in the infected cells which activated the protein p53 and the caspase-dependent cell death pathway..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies, and 40% of cases are related to mutation of the oncogene KRAS. However, no KRAS-targeting drugs are currently available for cancer treatment, and patients with KRAS mutations are insensitive to anti-EGFR therapy, which is often used for CRC. To improve treatment options, a new study tested the combined effects of the drugs artesunate and WNT974 on KRAS-mutant CRC. In vitro, the combination synergistically reduced CRC growth and decreased KRAS protein levels and activity, while inducing KRAS degradation via the ubiquitin–proteasome pathway, thereby reducing the oncogene’s influence. Specifically, the induced KRAS degradation was mediated by upregulation of ANAPC2, as well as upregulation of β-TrCP and GSK-3β. In addition, the combination treatment suppressed the PI3K/Akt/mTOR pathway, which is downstream of KRAS and supports tumor growth..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
No restrictions on your remixing, redistributing, or making derivative works. Give credit to the author, as required.
Your remixing, redistributing, or making derivatives works comes with some restrictions, including how it is shared.
Your redistributing comes with some restrictions. Do not remix or make derivative works.
Most restrictive license type. Prohibits most uses, sharing, and any changes.
Copyrighted materials, available under Fair Use and the TEACH Act for US-based educators, or other custom arrangements. Go to the resource provider to see their individual restrictions.